Who is sponsoring NCT04522102?

NCT04522102 is sponsored by The George Institute for Global Health, China.

What condition does NCT04522102 study?

NCT04522102 studies Intracerebral Hemorrhage.

What drugs are being tested in NCT04522102?

Interventions: Start antiplatelet monotherapy.

What is the status of NCT04522102?

NCT04522102 is currently COMPLETED.

Last reviewed 2025-03-26 · How we verify

Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase

NCT04522102 PHASE3 COMPLETED

ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet therapy for reducing all serious vascular events for adults surviving symptomatic stroke due to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve \~120 patients at \~30 hospitals in China, Australia and New Zealand.

Details

Lead sponsor	The George Institute for Global Health, China
Phase	PHASE3
Status	COMPLETED
Enrolment	80
Start date	Fri Sep 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Intracerebral Hemorrhage

Interventions

Start antiplatelet monotherapy

Countries

China